AAIC 2016 talks, page-63

Prana Biotechnology Limited



PBT Details

Strong cash position: Prana Biotechnology Ltd (ASX: PBT) has a strong cash position on balance sheet at $24.813 million at the end of March 2016. PBT also received orphan drug designation from European Commission and US FDA. Its PBT2 is currently on partial clinical hold by the US FDA.



Solid pipeline (Source: Company Reports)

PBT received $6.5 million cash refund from Australian government towards R&D tax incentive scheme for R&D in FY15. PBT would deploy these funds for further development of PBT2 for Huntington disease and PBT434 for the treatment of atypical Parkinsonian movement disorders. PBT recently clarified its ASX query while the stock delivered over 38.2% in the last three months (as on July 20, 2016). We give a “Speculative Buy” recommendation on the stock at the current price of $0.098


PBTDaily Chart (Source: Thomson Reuters)

http://www.kalkine.com.au/stockresearch/six-bio-tech-stocks-to-look-at.aspx